Dose-related selection of fluoroquinolone-resistant Escherichia coli.
暂无分享,去创建一个
Diarmaid Hughes | O. Cars | D. Hughes | Otto Cars | Linda L. Marcusson | Sara K Olofsson | Linda L Marcusson | Ann Strömbäck | A. Strömbäck | S. Olofsson
[1] O. Cars,et al. Bacteria with increased mutation frequency and antibiotic resistance are enriched in the commensal flora of patients with high antibiotic usage. , 2003, The Journal of antimicrobial chemotherapy.
[2] P. Neuvonen,et al. Inhibition of norfloxacin absorption by dairy products , 1992, Antimicrobial Agents and Chemotherapy.
[3] Xilin Zhao,et al. Mutant selection window hypothesis updated. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[4] O. Cars,et al. Pharmacokinetic and Pharmacodynamic Parameters for Antimicrobial Effects of Cefotaxime and Amoxicillin in an In Vitro Kinetic Model , 2001, Antimicrobial Agents and Chemotherapy.
[5] S. Hultgren,et al. Interaction of uropathogenic Escherichia coli with host uroepithelium. , 2005, Current opinion in microbiology.
[6] E. Bergoin,et al. In vivo pharmacodynamic efficacy of gatifloxacin against Streptococcus pneumoniae in an experimental model of pneumonia: impact of the low levels of fluoroquinolone resistance on the enrichment of resistant mutants. , 2004, The Journal of antimicrobial chemotherapy.
[7] O. Cars,et al. Selection of ciprofloxacin resistance in Escherichia coli in an in vitro kinetic model: relation between drug exposure and mutant prevention concentration. , 2006, The Journal of antimicrobial chemotherapy.
[8] P. McNamara,et al. Evolution of Ciprofloxacin-Resistant Staphylococcus aureus in In Vitro Pharmacokinetic Environments , 2004, Antimicrobial Agents and Chemotherapy.
[9] O. Cars,et al. Pharmacodynamics of moxifloxacin and levofloxacin against Streptococcus pneumoniae, Staphylococcus aureus, Klebsiella pneumoniae and Escherichia coli: simulation of human plasma concentrations after intravenous dosage in an in vitro kinetic model. , 2006, The Journal of antimicrobial chemotherapy.
[10] F. Aarestrup,et al. The effects of oral and intramuscular administration and dose escalation of enrofloxacin on the selection of quinolone resistance among Salmonella and coliforms in pigs. , 2003, Research in veterinary science.
[11] G. Kahlmeter. An international survey of the antimicrobial susceptibility of pathogens from uncomplicated urinary tract infections: the ECO.SENS Project. , 2003, The Journal of antimicrobial chemotherapy.
[12] V. Andriole. The quinolones: past, present, and future. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[13] Xilin Zhao,et al. Emergence of resistant Streptococcus pneumoniae in an in vitro dynamic model that simulates moxifloxacin concentrations inside and outside the mutant selection window: related changes in susceptibility, resistance frequency and bacterial killing. , 2003, The Journal of antimicrobial chemotherapy.
[14] O. Cars,et al. Pharmacodynamic effects of sub-MICs of benzylpenicillin against Streptococcus pyogenes in a newly developed in vitro kinetic model , 1996, Antimicrobial agents and chemotherapy.
[15] Xilin Zhao,et al. Restricting the selection of antibiotic-resistant mutants: a general strategy derived from fluoroquinolone studies. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[16] J J Schentag,et al. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients , 1993, Antimicrobial Agents and Chemotherapy.
[17] C. Stratton. Dead Bugs Don’t Mutate: Susceptibility Issues in the Emergence of Bacterial Resistance , 2003, Emerging infectious diseases.
[18] A. P. Arzamastsev,et al. ABT492 and levofloxacin: comparison of their pharmacodynamics and their abilities to prevent the selection of resistant Staphylococcus aureus in an in vitro dynamic model. , 2004, The Journal of antimicrobial chemotherapy.
[19] D. Sandvang,et al. Biological Cost of Single and Multiple Norfloxacin Resistance Mutations in Escherichia coli Implicated in Urinary Tract Infections , 2005, Antimicrobial Agents and Chemotherapy.
[20] F. Lowy,et al. Antimicrobial-resistant bacteria in the community setting , 2006, Nature Reviews Microbiology.
[21] J. Domagala,et al. Mutant Prevention Concentration as a Measure of Fluoroquinolone Potency against Mycobacteria , 2000, Antimicrobial Agents and Chemotherapy.
[22] N. W. Davis,et al. The complete genome sequence of Escherichia coli K-12. , 1997, Science.
[23] H. Stass,et al. Pharmacokinetics and elimination of moxifloxacin after oral and intravenous administration in man. , 1999, The Journal of antimicrobial chemotherapy.
[24] J. Blondeau,et al. Low Correlation between MIC and Mutant Prevention Concentration , 2006, Antimicrobial Agents and Chemotherapy.
[25] K. Drlica,et al. In Vitro Pharmacodynamic Evaluation of the Mutant Selection Window Hypothesis Using Four Fluoroquinolones against Staphylococcus aureus , 2003, Antimicrobial Agents and Chemotherapy.
[26] Xinjing Wang,et al. Selection of rifampicin-resistant Staphylococcus aureus during tuberculosis therapy: concurrent bacterial eradication and acquisition of resistance. , 2005, The Journal of antimicrobial chemotherapy.
[27] S. Zinner,et al. Testing the mutant selection window hypothesis with Staphylococcus aureus exposed to daptomycin and vancomycin in an in vitro dynamic model. , 2006, The Journal of antimicrobial chemotherapy.
[28] J. Rotschafer,et al. Application of fluoroquinolone pharmacodynamics. , 2000, The Journal of antimicrobial chemotherapy.
[29] D. Talan,et al. Extended-release ciprofloxacin (Cipro XR) for treatment of urinary tract infections. , 2004, International journal of antimicrobial agents.
[30] M. Klepser,et al. Comparative Bactericidal Activities of Ciprofloxacin, Clinafloxacin, Grepafloxacin, Levofloxacin, Moxifloxacin, and Trovafloxacin against Streptococcus pneumoniae in a Dynamic In Vitro Model , 2001, Antimicrobial Agents and Chemotherapy.
[31] D. Low,et al. Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia. , 2002, The New England journal of medicine.
[32] M. Brunner,et al. Microdialysis for in vivo pharmacokinetic/pharmacodynamic characterization of anti-infective drugs. , 2005, Current opinion in pharmacology.
[33] D. Hughes,et al. Mutation Rate and Evolution of Fluoroquinolone Resistance in Escherichia coli Isolates from Patients with Urinary Tract Infections , 2003, Antimicrobial Agents and Chemotherapy.
[34] A. Tomasz,et al. Evolution of a Vancomycin-Intermediate Staphylococcus aureus Strain In Vivo: Multiple Changes in the Antibiotic Resistance Phenotypes of a Single Lineage of Methicillin-Resistant S. aureus under the Impact of Antibiotics Administered for Chemotherapy , 2003, Journal of Clinical Microbiology.
[35] Naber. Treatment options for acute uncomplicated cystitis in adults. , 2000, The Journal of antimicrobial chemotherapy.
[36] G. Kaatz,et al. Activities of Mutant Prevention Concentration-Targeted Moxifloxacin and Levofloxacin against Streptococcus pneumoniae in an In Vitro Pharmacodynamic Model , 2003, Antimicrobial Agents and Chemotherapy.
[37] O. Cars. Pharmacokinetics of antibiotics in tissues and tissue fluids: a review. , 1990, Scandinavian journal of infectious diseases. Supplementum.
[38] K. Madaras-Kelly,et al. In vitro characterization of fluoroquinolone concentration/MIC antimicrobial activity and resistance while simulating clinical pharmacokinetics of levofloxacin, ofloxacin, or ciprofloxacin against Streptococcus pneumoniae. , 2000, Diagnostic microbiology and infectious disease.
[39] Xilin Zhao,et al. The mutant selection window in rabbits infected with Staphylococcus aureus. , 2006, The Journal of infectious diseases.
[40] S. Zinner,et al. Prevention of the selection of resistant Staphylococcus aureus by moxifloxacin plus doxycycline in an in vitro dynamic model: an additive effect of the combination. , 2004, International journal of antimicrobial agents.
[41] O. Cars,et al. Mutant prevention concentrations of ciprofloxacin for urinary tract infection isolates of Escherichia coli. , 2005, The Journal of antimicrobial chemotherapy.
[42] F. M. Stewart,et al. Resource-Limited Growth, Competition, and Predation: A Model and Experimental Studies with Bacteria and Bacteriophage , 1977, The American Naturalist.